A new study has shown an explosion in sales of baclofen for alcoholism:
The study can be found at http://www.celtiblog.com/baclofene-les-ventes-explosent/?utm_source=rss&utm_medium=rss&utm_campaign=baclofene-les-ventes-explosent
Here is what it says:
Consumption of this drug used in a roundabout way in the treatment of alcohol dependence, explodes. How long the authorities will they let him?
A study by Celtipharm data from its panel Xpr SO-powered real-time sales 3004 Representative pharmacies across the market shows an alarming increase in the use of Baclofen. If proof were needed that drug marketed by Sanofi and Novartis has greatly benefited from media coverage about a possible efficacy in the treatment of alcohol dependence. The period from September 2011 to the end of August 2012, the outputs consumer pharmacies pharmacy baclofen have shown that 3.2 million boxes (and its generic Lioresal ®) have been issued. An increase of 43.6% compared to the period from September 2008 to August 2009. Over the past twelve months the increase was 30.7%. On the assumption a dose of 80 mg per day per patient (maximum dosage allowed in permission marketing), we can estimate that on average around 39,000 patients were treated with baclofen over the same period .
Celtipharm has also looked at the sales meeting or exceeding 3 mg of baclofen, the threshold corresponding to the maximum permitted in the authorization for placing on the market over a period of one month of treatment. It is known that taking this medication in the context of the fight against alcohol dependence requires the most high (or very high) doses. Between the end of August 2009 and the end of August 2012, the share of drug sales in excess of the maximum authorized dose is increased from 3.2% to 6.2%. Another line of analysis, finally, that of co-delivered treatments with baclofen (especially co-tracking deliveries with benzodiazepines and antiepileptics) estimates that about 45,000 patients treated with baclofen in August last would be nearly 11,000 under alcohol withdrawal.
Taken together, these results constitute the “encrypted illuminating symptom that this molecule is increasingly used for purposes other than neurological, which led to the placing on the French pharmaceutical market in 1974 (1999 for generic), “said on his blog Jean-Yves Nau, a former journalist with the daily Le Monde and Chair journalism and public health EHESP. In fact, insofar as baclofen, when it is considered effective, is a priori to be taken for life the number of consumers can not, mathematically, that grow, adding new patients to the elders.
Omerta on baclofen
“Dramatic Acceleration sales of a drug only available on prescription and which is public knowledge that is consumed outside the health regulations in force. Who moves in? “Jean-Yves Nau questions. Response, not many people, and for good reason, it is nobody’s interest to talk about. Explanation: “The patients involved (who know the tortures of his alcoholism and withdrawal) only require to consume this product when it helps them regain their independence. Prescribers them (GPs most often) know what may be the effects of this molecule in their alcoholic patients. They do not respect the regulations, know that and have no interest in knowing what it is – not their patients.
Pharmaceutical companies involved explain that the use made of their specialty does not concern them (which remains to be demonstrated). They add not being able to use the part of the “official” (antispastic, muscle relaxant) its use “hijacked” (anti-alcohol dependence). As for Social Security, it reimburses the rules are followed or not. She does not want to know much more about this as it may think it is not really his doing (which is also shown). ‘
“If the efficacy of baclofen in the treatment of alcohol dependence has not yet been demonstrated to date, stated in April 2012, the National Security Agency of Medicines (MSNA), new observational data show clinical benefit in some patients. “For MSNA, the increase of adverse effects associated with the consumption of the product through the system of pharmacovigilance is very limited. Enough in any case not to jeopardize the continued treatment for people addicted to alcohol. To better understand the safety profile of the drug, the agency stated in the wake have authorized the launch of a controlled clinical trial, patients with alcohol consumption at high risk.And promised new on the subject later in October. Meanwhile, consumption rose baclofen without any certainty exists about the risks of this practice. Is this reasonable?